Streetbeat News

Revenues

BLDP

Ballard Power Systems anticipates its 2024 revenue to be heavily weighted towards the second half of the year, with an expected distribution of 30% in the first half and 70% in the second half, mirroring the pattern observed in 2023. The company has not provided specific revenue or net income guidance for 2024, citing the nascent stage of the hydrogen fuel cell market.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:35 pm

ROST

Ross Stores, Inc. has opened 18 new stores across 11 states, including 11 Ross Dress for Less and seven dd's DISCOUNTS locations. This expansion is part of their plan to open approximately 90 new stores in fiscal 2024, aiming for a total of 75 Ross and 15 dd's DISCOUNTS stores. The company now operates 2,127 locations nationwide and has a long-term goal of reaching 2,900 Ross and 700 dd's DISCOUNTS stores, driven by consumer demand for value and convenience.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:33 pm

CXM

Sprinklr, Inc. (NYSE:CXM) announced the launch of a local data hosting solution in Saudi Arabia, hosted on Google Cloud, aiming to expand in the Middle East and comply with regional regulations. This move, marking Sprinklr as the first customer experience platform with local hosting in Saudi Arabia on Google Cloud, is expected to provide a competitive advantage. The company reported an 18% Y/Y revenue increase for Q3 FY24 to $186.3 million, surpassing consensus estimates. CXM shares rose 0.38% in premarket trading.

Portfolio Pulse from Lekha Gupta

March 11, 2024 | 12:20 pm

MIND

MIND Technology's Seamap unit has been awarded an order by ATLAS MARIDAN, indicating a positive development for MIND and potentially boosting its financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:14 pm

ANIP

DOV

GOOGL

RCM

Insiders at Alphabet, Dover, ANI Pharmaceuticals, and R1 RCM have recently sold shares. These sales could indicate various sentiments about the companies' prospects or stock valuations. Notably, ANI Pharmaceuticals reported positive earnings, R1 RCM showed disappointing sales, Dover's revenue declined, and Alphabet's new Pixel 8 will lack a key feature.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 12:10 pm

BIOR

Biora Therapeutics, Inc. (NASDAQ:BIOR) has announced a series of financial transactions aimed at reducing its net debt and raising new capital. The company has exchanged convertible notes for new capital and senior secured notes, bringing in $2.8 million. Additionally, Biora has monetized its investment in Enumera Molecular, Inc., resulting in $3 million of nondilutive funding. These transactions are part of Biora's efforts to optimize its capital structure and fund its therapeutic programs. The company has reduced its debt by over $80 million since September 2023 through note exchange transactions, with institutional investors contributing $19.8 million of new capital.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:02 pm

CHH

Recent analyst ratings for Choice Hotels Intl (NYSE:CHH) show a mixed sentiment, with a shift towards a more cautious outlook. Over the last three months, 5 analysts have updated their views, leading to an average 12-month price target of $124.6, up 13.02% from the previous target. The company's financial health indicators such as net margin and ROE outperform industry averages, despite a negative revenue trend and high debt-to-equity ratio. Choice Hotels operates 633,000 rooms across 15 brands, with franchises accounting for 100% of total revenue.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 12:02 pm

ULTA

In the last three months, 4 analysts have updated their ratings on Ulta Beauty (NASDAQ:ULTA), showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $605, up 9.01% from the previous $555, with a high estimate of $690 and a low of $530. Ulta Beauty, with 1,355 stores and a partnership with Target, is a leading beauty retailer in the U.S. The company has shown strong financial performance, with a revenue growth rate of 6.42%, a net margin of 10.02%, and an ROE of 12.23%. Analysts' updates and financial metrics suggest a positive outlook for Ulta Beauty.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 12:02 pm

ARCT

Arcturus Therapeutics (NASDAQ:ARCT) has seen a variety of analyst ratings over the past three months, with a recent positive shift in sentiment. Four analysts have provided ratings, with the latest 12-month price targets showing an average of $63.25, up 14.31% from the previous $55.33. The company's financial performance has been strong, with significant revenue growth and above-average financial metrics compared to the industry. Arcturus focuses on RNA medicines for rare diseases, with a notable pipeline including LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 12:01 pm

S

SentinelOne (NYSE:S) has seen diverse analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target has increased to $30.43, indicating a 29.49% rise from the previous target. Analysts from firms like Wells Fargo, Guggenheim, and Goldman Sachs have raised their price targets, reflecting optimism about SentinelOne's market performance. Despite challenges in profitability and asset utilization, SentinelOne's revenue growth outpaces its peers, and its low debt-to-equity ratio suggests a healthy balance between debt and equity.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 12:01 pm